Navigation Links
PTC Therapeutics Expands Management Team
Date:10/1/2013

09 as Executive Director of Clinical Development. He was promoted to Vice President in 2011. Prior to joining PTC, Dr. Barth was Executive Director of Clinical Research at Merck from July 2007 to October 2008. From June 2005 to June 2007, he served as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc. Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery and development of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and are the basis for collaborations with leading biopharmaceutical companies. For more information, visit the company's web site at www.ptcbio.com.

Forward Looking Statements:
Any statements in this press release about future expectations, plans and prospects for the Company, the development of and potential market for the Company's product candidates and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan" "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from those expressed or implied by thes
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... -- According to the new research ... Wastewater Treatment and Industrial Wastewater Treatment), By Type ... Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends & ... for membrane bioreactor systems is projected to reach ... of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 ... biotechnology company whose patented and proprietary technologies are ... other proteins for the bioenergy, bio-based chemical, biopharmaceutical ... has filed a Registration Statement on Form 10 ... "SEC"). Logo - http://photos.prnewswire.com/prnh/20110621/CL06708LOGO ...
(Date:8/18/2014)... 18. August 2014 Vier führende ... internationale klinische Studie auf, in der eine ... soll das Sehvermögen bei allen Entfernungen verbessern, ... möglicherweise keine Lese- oder Gleitsichtbrille mehr benötigen. ... FluidVision Accommodating Intraocular Lens (FluidVision ...
(Date:8/16/2014)... the Walmart Foundation to build a robotic small motors ... costs of goods, allowing those goods to be produced ... , The Walmart U.S. Manufacturing Innovation Grant was part ... seven research and development institutions at the 2014 U.S. ... between Walmart, the U.S. Conference of Mayors and the ...
Breaking Biology Technology:Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... , , SEATTLE, Aug. 11 ... 2 clinical trial of OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) ... anti-inflammatory agent and an agent that causes pupil dilation ... , Omeros, Phase 1/Phase 2 trial ...
... , , SEATTLE, Aug. 11 ... quarter ended June 30, 2009. Revenue for the second quarter of 2009 ... Revenue for the six months ended June 30, 2009 was $55,000 compared to ... Dendreon,s total operating expenses for the second quarter of 2009 were ...
... Diverse Student ... , ... 11, 2009 - As a new class of eager high school seniors begins the college ... mark, a new study reveals what Americans consider to be the defining characteristics of a ...
Cached Biology Technology:Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2Dendreon Reports Second Quarter 2009 Financial Results 2Dendreon Reports Second Quarter 2009 Financial Results 3Dendreon Reports Second Quarter 2009 Financial Results 4Dendreon Reports Second Quarter 2009 Financial Results 5Dendreon Reports Second Quarter 2009 Financial Results 6What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 2What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 3What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 4What Makes a University Great? Americans Say Renowned Faculty, Top-Rank Research Center are Most Important, According to New Survey from IP Advocate 5
(Date:8/19/2014)... devised a new implantable tissue scaffold coated with bone ... weeks. When applied to bone injuries or defects, this ... bone that looks and behaves just like the original ... a dramatic improvement over the current standard for treating ... of the patient,s body a painful process that ...
(Date:8/19/2014)... infants born with neonatal abstinence syndrome (NAS) secondary ... time going through withdrawal than others, but the ... and epigenetic (when genes are turned on or ... factors, researchers at Boston University School of Medicine ... first of its kind study to identify some ...
(Date:8/19/2014)... The ancestors of today,s crocodiles colonised the seas during ... to a new Anglo-French study which establishes a link ... temperature over a period of more than 140 million ... Martin from the Universit de Lyon, France and formerly ... week in Nature Communications ., Today, crocodiles are ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
... age-old tradition that dates back at least 8,000 years ... about the bacteria responsible for turning milk into cheese., ... has identified a new line of bacteria they believe ... cheeses. , The team used DNA fingerprinting techniques to ...
... 6, 2009 Elsevier, a leading global healthcare and ... in the Elsevier Grand Challenge, a competition inviting ... amount of online life sciences information. ( ... on December 15th at the Massachusetts Institute of ...
... 2009, St. Louis, MO As adolescents mature into young adults, ... impact eating habits in a negative way. In a study published ... American Dietetic Association , researchers observed that while young adults enjoy ... 42% of females reported lacking time to sit down and eat ...
Cached Biology News:Wonderful cheese is all in the culture 2Finalists announced in the Elsevier Grand Challenge 2Finalists announced in the Elsevier Grand Challenge 3Young adults need to make more time for healthy meals 2
... Bruker Daltonics and Bruker BioSpins ... for metabolism studies, and analysis of ... ESI-TOF system, an optional Avance NMR ... acquisition, evaluation and statistical analysis for ...
... Tracker w/ OutputCumulates a score of movement counts, ... that it.can track up to 6 subjects at ... be triggered. Can outpt a sync pulse ... Can use animal location and timing information ...
... fermentation systems for cultivation of microorganisms and ... of bio-pharmaceutical products maximum performance and economy ... and cell fermentation 10 L 1,500 ... ,*Fully automated control system ,*High-quality ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Biology Products: